Literature DB >> 10880291

Recovery of visual field constriction following discontinuation of vigabatrin.

K Krakow1, G Polizzi, P Riordan-Eva, G Holder, W N MacLeod, D R Fish.   

Abstract

Epilepsy patients treated with vigabatrin may develop symptomatic or asymptomatic concentric visual field constriction due to GABA-associated retinal dysfunction. The prevalence and course of this side effect are not established yet; in previously reported adult patients the visual disturbances seem to be irreversible. We present two patients with a significant improvement of visual field constriction and retinal function after the discontinuation of vigabatrin. These findings suggest that vigabatrin-associated retinal changes are at least partly reversible in some patients, and that these patients may benefit significantly from a withdrawal of vigabatrin. Larger scale clinical studies are needed to identify predictive factors both for the occurrence and reversibility of vigabatrin-associated visual field defects. Copyright 2000 BEA Trading Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10880291     DOI: 10.1053/seiz.2000.0397

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  7 in total

1.  Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin.

Authors:  Ulrika Kjellström; Sten Kjellström; Anitha Bruun; Sten Andréasson; Vesna Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-01       Impact factor: 2.379

2.  Vigabatrin associated retinal dysfunction in children with epilepsy.

Authors:  R Koul; A Chacko; A Ganesh; S Bulusu; K Al Riyami
Journal:  Arch Dis Child       Date:  2001-12       Impact factor: 3.791

3.  Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.

Authors:  Wynne K Schiffer; Douglas Marsteller; Stephen L Dewey
Journal:  Psychopharmacology (Berl)       Date:  2003-04-09       Impact factor: 4.530

4.  Vigabatrin and visual field defects in pediatric epilepsy patients.

Authors:  Su Jeong You; HyoSook Ahn; Tae-Sung Ko
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

5.  Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.

Authors:  Ulrika Kjellström; Monica Lövestam-Adrian; Sten Andréasson; Vesna Ponjavic
Journal:  Doc Ophthalmol       Date:  2008-01-10       Impact factor: 2.379

Review 6.  Visual field defects and other ophthalmological disturbances associated with vigabatrin.

Authors:  S J Spence; R Sankar
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

Review 7.  Visual field defects with vigabatrin: epidemiology and therapeutic implications.

Authors:  R Kälviäinen; I Nousiainen
Journal:  CNS Drugs       Date:  2001       Impact factor: 6.497

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.